Reduction of atherothrombotic events in patients w/ history of recent MI/stroke or established peripheral arterial disease; MI & stroke in patients w/ non-ST-segment elevation acute coronary syndrome [(ACS) unstable angina/non-ST-elevation MI (NSTEMI)] including patients who are to be managed & those who are to be managed w/ coronary revascularization.
ACS Initially, single 300-mg oral loading dose & continue at 75 mg once daily. Recent MI/stroke, or established peripheral arterial disease 75 mg once daily orally w/o loading dose.
Hypersensitivity including rash, angioedema or hematologic reaction to other thienopyridines; diminished antiplatelet activity in patients w/ impaired CYP2C19 function; increase risk of bleeding; discontinue if there is an increased risk of CV events; TTP. Severe & moderate renal impairment. Hepatic impairment. Pregnancy category B. Lactation. Safety & efficacy have not been established in childn. Elderly.
Avoid concomitant use w/ omeprazole or esomeprazole due to the reduction of antiplatelet activity. Increase risk of GI bleeding w/ NSAIDs; warfarin; SSRIs & SNRIs. Increase systemic exposure w/ repaglinide.